Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

By | July 6, 2021
A team of US-based scientists recently demonstrated that pro-thrombotic autoantibodies that target angiotensin II type 1 receptor (AT1R) may be associated with endothelial complications observed in coronavirus disease 2019 (COVID-19), a novel disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).